The biomarker is expected to pave the way for reducing the degree of Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a common complication of cancer treatment with chemotherapy, especially in the treatment of breast, lung and colorectal cancer, states the company.

“It is well known that the nervous system is affected by chemotherapy, with a high risk of having permanent nerve damage. Many treatments also have to be discontinued in advance as a result of the nerve damage becoming too severe. With our new discovery, we can help doctors and nurses to identify people with an increased risk of nerve damage at an early stage. This makes it possible to make the treatment more individualized,” says Toni Speidel, CTO at VibroSense Dynamics AB.

The patent covers both the device and the method and strengthens the company’s IP protection. In addition to patents, VibroSense Dynamics’ products are protected by encrypted algorithms in the software of the VibroSense Meter II instrument.